ChroMedX Announces Expansion and Launch as Relay Medical Corp.
Toronto, Ontario--(Newsfile Corp. - June 19, 2018) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to report on the Company's expansion into a Medtech incubator/accelerator platform and launch as Relay Medical Corp. The formal name change will take place following the Company's Annual General Meeting on June 29, 2018. Since his appointment as CEO in January 2018, Lahav Gil has led the build-out of...
2018-06-19 4:10 PM EDT
ChroMedX Acquires UX Data Sciences Corp.
Toronto, Ontario--(Newsfile Corp. - May 24, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the closing of its previously announced acquisition (the "Transaction") of the Ottawa, Ontario based medtech data science company, UX Data Sciences Corp. ("UXD"). "The depth and breadth of the UXD vision and technology promises to change the paradigm for medication from linear to matrix,...
2018-05-24 7:36 PM EDT
ChroMedX Signs Deal to Acquire UX Data Sciences Corp.
Toronto, Ontario--(Newsfile Corp. - May 9, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce that it has entered into a binding Letter-of-Intent ("LOI") to acquire Ottawa, Ontario based medtech data science company, UX Data Sciences Corp. ("UXD"). UX Data Sciences Corp. is a private Ottawa-based medical technology and data science company developing UX-centric products and systems...
2018-05-09 11:41 AM EDT
ChroMedX Reports on HemoPalm Techno-Commercial Analysis and Productization Plan
Toronto, Ontario--(Newsfile Corp. - May 8, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company") developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to report on HemoPalm activities. In early January 2018, ChroMedX announced the appointment of Lahav Gil as Chief Executive Officer and Director. Since that time Lahav has led the expansion of the Company's development infrastructure and team to conduct a techno-commercial analysis and feasibility study...
2018-05-08 9:13 AM EDT
ChroMedX Appoints Michaela Shaw as Director of Quality Assurance and Regulatory Assurance
Toronto, Ontario--(Newsfile Corp. - April 13, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Michaela Shaw as Director of Quality Assurance and Regulatory Assurance. As Director of QA/RA Ms. Shaw's immediate mandate is to accelerate the Company's QMS towards ISO 13485 compliance by Q2 2019, as the Company expands its team, scope, and projects. "I have worked...
2018-04-13 4:05 PM EDT
ChroMedX CEO Lahav Gil Invited to Speak on Industry Panel at bioTEC, Biotechnology and Bioengineering Conference
Toronto, Ontario--(Newsfile Corp. - March 27, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company") , developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce that CEO Lahav Gil will speak at the 2018 bioTEC Conference at the University of Waterloo to discuss innovation culture and Medtech commercialization. Lahav is an invited speaker on the industry panel at the bioTEC Biotech and Bioengineering Conference, the first of its kind in Canada....
2018-03-27 4:35 PM EDT
ChroMedX Accelerates Software Development and Implementation Activities; Appoints iGAL Roytblat, Formerly of Kangaroo Group, as CTO, Amid Expansion
Toronto, Ontario--(Newsfile Corp. - March 21, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce an update on the acceleration of software development and implementation activities led by newly appointed Chief Technology Officer (CTO) iGAL Roytblat. The new HemoPalm Software Architecture is built on a scriptable engine with visual authoring tools that enable an accelerated R&D cycle,...
2018-03-21 6:27 PM EDT
ChroMedX Appoints Raj Kailasanathan as Executive Vice President Corporate Finance
Toronto, Ontario--(Newsfile Corp. - March 19, 2018) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Raj Kailasanathan as ChroMedX Corp. Executive Vice President, Corporate Finance. Mr. Kailasanathan joins ChroMedX as a seasoned finance executive with over 20 years experience in the private and public industry in Asia and North America. Prior to joining ChroMedX Corp.,...
2018-03-19 4:05 PM EDT
ChroMedX CEO Lahav Gil Assembles Task-Force to Explore Feasibility and Applications of Automated Ultrafiltration Technology
Toronto, Ontario--(Newsfile Corp. - February 15, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the formation of an evaluation team for the analysis of the Company's patented Automated Ultrafiltration Technology (AUF). The AUF technology will allow fast, automated preparation of ultra-filtrates of serum and plasma samples, for measurement of free therapeutic drugs and hormones. The...
2018-02-15 4:05 PM EST
ChroMedX Appoints Dr. Richard Janeczko as Chief Commercial Officer; Jessica Kuhn as Chief Operations Officer
Toronto, Ontario--(Newsfile Corp. - January 23, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointments of Dr. Richard Janeczko as Chief Commercial Officer (CCO) and Jessica Kuhn as Chief Operations Officer (COO). Dr. Janeczko and Ms. Kuhn's positions are effective immediately. "It is very exiting to start the scale-out of the ChroMedX executive team with the appointments of...
2018-01-23 4:05 PM EST
ChroMedX Corp. Expands Executive Team; Lahav Gil Appointed CEO and Director
Toronto, Ontario--(Newsfile Corp. - January 5, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointments of MedTech visionary Lahav Gil as Chief Executive Officer and W. Clark Kent as President of the Company. Both have also been appointed to the Company's board of directors. Mr. Gil joins ChroMedX as the founder and former CEO of the innovative Toronto-based medical device...
2018-01-05 4:07 PM EST
ChroMedX Corp. Executes Definitive Agreement with DxEconomix to Lead Value-Based Transactions
Toronto, Ontario--(Newsfile Corp. - January 3, 2018) - ChroMedX Corp. (CSE: CHX) (OTC: CHXIF) (FSE: EIY2), (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to report on the signing of a definitive agreement with diagnostic marketing experts DxEconomix Inc. (DxEx) to conduct a high value transaction for the Company. In August 2017 ChroMedX retained the consulting company for an evaluation of the HemoPalm Analyzer's product viability, value offering, and...
2018-01-03 4:05 PM EST
ChroMedX Announces Exercise of Warrants
Toronto, Ontario--(Newsfile Corp. - December 13, 2017) - ChroMedX Corp. (CSE: CHX) (OTC: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that since November 2017 investors have exercised warrants to acquire 1,031,000 new common shares of the Company as of December 12, 2017. The total consideration received was CAD$226,200. The Warrant Shares will rank pari passu in all respects with the existing common shares of the Company....
2017-12-13 4:05 PM EST
ChroMedX Strengthens Board of Directors with the Appointment of Dr. Richard Janeczko
Toronto, Ontario--(Newsfile Corp. - December 7, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointment of Dr. Richard Janeczko to the Company's Board of Directors. This appointment is consistent with the Company's strategy to strengthen its business development and commercialization team through the addition of an experienced executive who brings hands-on business,...
2017-12-07 6:55 PM EST
ChroMedX Announces In-House Biosensor Manufacturing for Expedited Testing and Refinement; Appoints Edwards as Executive Chairman
Toronto, Ontario--(Newsfile Corp. - December 1, 2017) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to report that the Company is now in the process of mass manufacturing the HemoPalm's biosensor component at the ChroMedX lab in Ontario, Canada. The Company also announces the appointment of Gerard Edwards as Executive Chairman, and George Langdon as Corporate Communications Director. In August of...
2017-12-01 4:15 PM EST
ChroMedX Accepts Proposal; Signs LOI with Diagnostic Marketing Experts to Conduct a Value-Based Transaction for the HemoPalm Blood Analyzer System
Toronto, Ontario--(Newsfile Corp. - November 24, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that it has entered into a binding Letter of Intent ("LOI") with Glendale, California headquartered diagnostic marketing specialist Dx Econmix Inc. (DxEx) to conduct a high value transaction for the Company. The Company is now working with DxEconomix to establish a definitive agreement...
2017-11-24 5:19 PM EST
ChroMedX Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - November 20, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed a non-brokered private placement (the "Offering") of 7,570,500 units ("Units") at a price of $0.20 per Unit for aggregate gross proceeds of $1,514,100. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to...
2017-11-20 5:20 PM EST
ChroMedX appoints Ants Kahu & Associates to Implement Quality Management System
Toronto, Ontario--(Newsfile Corp. - November 13, 2017) - ChroMedX Corp. (the "Company") (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the engagement of Ants Kahu & Associates to implement Quality Management Systems to meet FDA and ISO requirements. Ants Kahu & Associates will work closely with ChroMedX to develop and implement the FDA Quality System Requirements (QSR) 21 CFR Part 820 and ISO 13485:2016. These Quality...
2017-11-13 4:02 PM EST
ChroMedX Retains DxEconomix for Commercialization Strategy
Toronto, Ontario--(Newsfile Corp. - August 21, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that it has retained Glendale, California based IVD marketing specialists DxEconomix Inc. DxEconomix led by Dr. Richard Janeczko will work with ChroMedX to evaluate/analyze the patented HemoPalm Blood Analyzer System's value offering, forecasting, commercialization and marketing plan in...
2017-08-21 4:15 PM EDT
ChroMedX Announces Lab Expansion for Accelerated Testing and Development
Toronto, Ontario--(Newsfile Corp. - August 2, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the expansion of its lab capabilities and relocation of Corporate and developmental headquarters to Oakville, Ontario. Since November 2014 ChroMedX's Canadian based development has taken place at the McMaster Innovation Park Lab under the leadership of Dr. Cynthia Balion and the Biointerface...
2017-08-02 4:10 PM EDT